<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fexofenadine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fexofenadine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fexofenadine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8445" href="/d/html/8445.html" rel="external">see "Fexofenadine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12470" href="/d/html/12470.html" rel="external">see "Fexofenadine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171069"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Allegra Allergy Childrens [OTC];</li>
<li>Allegra Allergy [OTC];</li>
<li>Allegra Hives 24HR [OTC];</li>
<li>Allergy 24-HR [OTC];</li>
<li>Allergy Childrens [OTC];</li>
<li>Allergy Relief [OTC];</li>
<li>Allergy Relief/Indoor/Outdoor [OTC];</li>
<li>FT Allergy Relief 12 Hour [OTC];</li>
<li>FT Allergy Relief 24 Hour [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058710"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihistamine</span></li></ul></div>
<div class="block dop drugH1Div" id="F171090"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63a9529f-6699-4035-a7f7-7efb81ec22fc">Allergic symptoms/rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic symptoms/rhinitis:</b> Product-specific dosing:</p>
<p style="text-indent:-2em;margin-left:4em;">Twice-daily formulations (eg, oral suspension, oral disintegrating tablet, regular tablet):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral suspension:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;2 years: Limited data available (Hampel 2007):</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;10.5 kg: Oral: 15 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥10.5 kg: Oral: 30 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">Dosing based on a safety and tolerability study on patients with allergic rhinitis receiving fexofenadine 15 mg twice daily (weight &lt;10.5 kg, n=85) and fexofenadine 30 mg twice daily (weight ≥10.5 kg, n=108) compared to placebo (n=199); adverse events were similar between fexofenadine and placebo (Hampel 2007).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 to &lt;12 years: Oral: 30 mg every 12 hours; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 60 mg every 12 hours; maximum daily dose: 120 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Orally-disintegrating tablet (ODT)</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years to &lt;12 years: Oral: 30 mg every 12 hours; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 60 mg every 12 hours; maximum daily dose: 120 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>12-hour tablet: </i>Children ≥12 years and Adolescents: Oral: 60 mg every 12 hours; maximum daily dose: 120 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Once-daily formulation:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 180 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d9d94d9-ca6f-40af-aa3f-2ce90b91c7c5">Urticaria, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, acute: </b> Limited data available (Kliegman 2020):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 to 11 years: Twice-daily formulations (eg, oral suspension, oral disintegrating tablet, regular tablet): Oral: 30 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Twice-daily formulations (eg, oral suspension, oral disintegrating tablet, regular tablet): Oral: 60 mg every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e59a61ec-4a7a-40f9-83a5-0a8d439e15d5">Urticaria, chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous: </b>Limited data available: <b>Note:</b> Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of fexofenadine (as age and weight permits) as second-line treatment rather than changing therapy (Zuberbier 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months to Children &lt;2 years: Twice-daily formulations (eg, oral suspension): Oral: 15 mg every 12 hours (Lee 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to &lt;12 years: Twice-daily formulations (eg, oral suspension, orally-disintegrating tablet, regular tablet): Oral: 30 mg twice daily (Pozzo-Magaña 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Twice-daily formulations (eg, oral suspension, orally-disintegrating tablet, regular tablet): Oral: 60 mg every 12 hours (Finn 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Once-daily formulation: Oral: 180 mg once daily (Kaplan 2005).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110032"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Twice-daily formulations (eg, oral suspension, oral disintegrating tablet, regular tablet):</p>
<p style="text-indent:-2em;margin-left:4em;">There are no dosage adjustments provided in the OTC manufacturer's labeling; previous prescribing information (Allegra prescribing information 2007) suggested the following:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months to Children &lt;2 years: Any degree of kidney impairment: Initial: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 11 years: Any degree of kidney impairment: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Any degree of kidney impairment: 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Others have suggested the following: Children ≥12 years and Adolescents (Aronoff 2007):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 50 mL/minute: 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Not effectively removed by hemodialysis: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Once-daily formulation: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51110033"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F171074"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8445" href="/d/html/8445.html" rel="external">see "Fexofenadine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f19228ca-0b9f-4938-821a-f482214139a6">Upper respiratory allergies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory allergies:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Twice-daily formulations: <b>Oral:</b> 60 mg every 12 hours (maximum: 120 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">Once-daily formulations: <b>Oral: </b>180 mg once daily (maximum: 180 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New onset: Oral:</b> Initial: 180 mg once daily. If symptom control is inadequate, may immediately increase to 180 mg twice daily (Asero 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic spontaneous: Oral:</b> 180 mg once daily (Kaplan 2005). If symptom control is inadequate, add a different second-generation antihistamine; higher doses of fexofenadine have not been shown to be more effective in controlling urticaria symptoms in most patients (Finn 1999; Khan 2021; Nelson 2000).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990809"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Use of the once-daily formulation is not recommended in patients with eGFR &lt;50 mL/minute/1.73 m<sup>2</sup> or on renal replacement therapies (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(Aronoff 2007; expert opinion):</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥50 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 10 to &lt;50 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>60 mg every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;10 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>60 mg every 24 hours. <b>Note:</b> Results of a pharmacokinetic study suggest that nonrenal clearance of fexofenadine is impaired in patients with end-stage kidney disease (ESKD) (Thomson 2015); monitor patients for signs and symptoms of drug accumulation and toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Bilbao-Meseguer 2018; Udy 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg every 24 hours (Aronoff 2007; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Results of a pharmacokinetic study suggest that nonrenal clearance of fexofenadine is impaired in patients with ESKD (Thomson 2015); monitor patients for signs and symptoms of drug accumulation and toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Significant removal unlikely (large V<sub>d</sub>) (expert opinion):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg every 24 hours (Aronoff 2007; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Results of a pharmacokinetic study suggest that nonrenal clearance of fexofenadine is impaired in patients with ESKD (Thomson 2015); monitor patients for signs and symptoms of drug accumulation and toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, excess sedation) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg every 24 hours (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, excess sedation) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg every 24 hours (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988011"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F171039"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Vomiting (infants and children: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (infants and children: 4%), stomach discomfort (adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adolescents and adults: 2%), drowsiness (infants and children: ≤3%), fatigue (infants and children: ≤3%)<b>, </b>headache (adolescents and adults: 5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (adolescents and adults: 2% to 3%), limb pain (adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children: 4%), rhinorrhea (infants and children: 2%), upper respiratory tract infection (children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (Wahn 2003), Stevens-Johnson syndrome (Teo 2017), toxic epidermal necrolysis (Teo 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (Meltzer 2004), nausea (Wahn 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity reaction: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia, nervousness, nightmares, sleep disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (Wahn 2003)</p></div>
<div class="block coi drugH1Div" id="F171053"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">OTC labeling: When used for self-medication do not use if you ever had an allergic reaction to fexofenadine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F171036"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Orally disintegrating tablet: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: When used for self-medication (OTC), do not exceed recommended dosage or administer at the same time with aluminum or magnesium antacids or with fruit juices.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878457"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F171047"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Allergy Childrens: 30 mg/5 mL (240 mL) [alcohol free, dye free; contains butylparaben, edetate (edta) disodium, propylene glycol, propylparaben; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Allergy Childrens: 30 mg/5 mL (120 mL) [alcohol free, dye free; contains butylparaben, edetate (edta) disodium, propylene glycol, propylparaben; raspberry creme flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Childrens: 30 mg/5 mL (118 mL, 237 mL) [alcohol free, dye free; contains butylparaben, edetate (edta) disodium, propylene glycol, propylparaben; berry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Allergy: 60 mg, 180 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Allergy: 180 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Hives 24HR: 180 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy 24-HR: 180 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 60 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 180 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 180 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief/Indoor/Outdoor: 180 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief 12 Hour: 60 mg [contains corn starch, fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief 24 Hour: 180 mg [contains corn starch, fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg, 180 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra Allergy Childrens: 30 mg [dye free; contains aspartame; orange cream flavor]</p></div>
<div class="block geq drugH1Div" id="F171032"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F171055"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Allegra Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/5 mL (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Allegra Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Allegra Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $0.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Allegra Hives 24HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fexofenadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.16 - $0.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $0.16 - $0.42</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612839"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Twice-daily formulations:</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension, regular tablet: May administer without respect to food. Take with water; avoid administration with fruit juices; shake suspension well before use. Administer suspension with an accurate measuring device; do not use a household teaspoon.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally-disintegrating tablet: Administer on an empty stomach. Do not remove from blister pack until ready to administer. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds and may be swallowed with or without liquid; avoid administering with fruit juices.</p>
<p style="text-indent:-2em;margin-left:2em;">Once-daily formulation: Swallow whole with water; do not take with fruit juices.</p></div>
<div class="block adm drugH1Div" id="F171050"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Administer on an empty stomach. Remove tablet from individual blister and place immediately on tongue; tablet will disintegrate with or without water (do not administer with fruit juices).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension, tablet: Administer with water only; do not administer with fruit juices. Shake suspension well before use. Use suspension only with enclosed dosing cup.</p></div>
<div class="block sts drugH1Div" id="F171065"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Use orally disintegrating tablet immediately after opening individual blister.</p></div>
<div class="block usep drugH1Div" id="F53566898"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Relief of symptoms due to hayfever or upper respiratory allergies (OTC products: Oral suspension: FDA approved in ages ≥2 years and adults; Meltable tablets: FDA approved in ages ≥6 years and adults; Tablets [12 or 24 hours]: FDA approved in ages ≥12 years and adults); has also been used to treat uncomplicated skin manifestations of urticaria. <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information. </p></div>
<div class="block mst drugH1Div" id="F171108"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allegra may be confused with Allegra Anti-Itch Cream (diphenhydramine/allantoin), Viagra</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fexofenadine may be confused with fesoterodine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex Allergy may be confused with Mucinex </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Allegra [US, Canada, and multiple international markets] may be confused with Allegro brand name for fluticasone [Israel] and frovatriptan [Germany]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F171096"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F171041"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Fexofenadine. Management: Separate the administration of fexofenadine and aluminum- or magnesium-containing antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May decrease the serum concentration of Fexofenadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Fexofenadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Fexofenadine. RifAMPin may increase the serum concentration of Fexofenadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F171066"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">High-fat meals decrease the bioavailability of fexofenadine by ~50%. Fruit juice (apple, grapefruit, orange) may decrease bioavailability of fexofenadine by ~36%. Management: Separating fexofenadine administration and fruit juice consumption by at least 4 hours may decrease the significance of this possible interaction.</p></div>
<div class="block dic drugH1Div" id="F6030683"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine and/or sodium. Take suspension and tablets preferably with water; separate administration with grapefruit or other fruit juices by at least 4 hours.</p></div>
<div class="block pri drugH1Div" id="F171056"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Agents other than fexofenadine are preferred for the treatment of allergic conditions, such as rhinitis, pruritus, and urticaria, in pregnant women (BSACI [Powell 2015]; BSACI [Scadding 2017]; Murase 2014; Zuberbier 2018).</p></div>
<div class="block mopp drugH1Div" id="F53566899"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Improvement in signs and symptoms of allergic rhinitis and chronic idiopathic urticaria</p></div>
<div class="block pha drugH1Div" id="F171035"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fexofenadine is an active metabolite of terfenadine and like terfenadine it competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract; it appears that fexofenadine does not cross the blood-brain barrier to any appreciable degree, resulting in a reduced potential for sedation</p></div>
<div class="block phk drugH1Div" id="F171052"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: 2 hours (Simons 2004)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of action: 24 hours (Simons 2004)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 60% to 70% (Markham 1998); primarily albumin and alpha<sub>1</sub>-acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Minimal (Hepatic: ~5%); 3.6% transformed into methylester metabolite found only in feces</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~33%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 14.4 hours (59% longer in patients with mild to moderate renal impairment [CrCl 41 to 80 mL/minute]; 72% longer in patients with severe renal impairment [CrCl 11 to 40 mL/minute]) (Markham 1998; Simons 2004)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: ODT: 2 hours (4 hours with high-fat meal); Tablet: ~2.6 hours (Simons 2004); Suspension: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (80%) and urine (12%) as unchanged drug (Simons 2004)</p></div>
<div class="block phksp drugH1Div" id="F51192564"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mild to moderate impairment with CrCl 41 to 80 mL/minute has an 87% increase in C<sub>max</sub>. Severe impairment with CrCl 11 to 40 mL/minute has a 111% increase in C<sub>max</sub>.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: C<sub>max</sub> is increased 99%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171057"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Celera | Fenadex | Fexigra | Fexodine | Fexogen | Fexon | Fexotel | Sarfast | Telfast | Telife | Zyhist</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alercas | Alerfedine | Allegra | Mudantil f | Vagran 120 | Vagran 180</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Telfast</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Allerfexo | Amcal Fexo | Apohealth fexofenadine hayfever &amp; allergy relief | Blooms the chemist fexofenadine | Chemists Own Fexo | Chemists' Own Fexo | Chemmart fexofenadine | Chemplus fexofenadine | Discount drug stores fexofenadine | Fexal | Fexo | Fexofenadine | Fexofenadine hayfever &amp; allergy relief | Fexorelief | Fexotabs | Guardian Fexo | Hayfexo | Pharmacist fexofenadine | Pharmacists own fexofenadine | Pharmacy care fexo | Pharmacy health fexofenadine | Priceline pharmacy fexofenadine hayfever &amp; allergy relief | Tefodine | Telfast | Terry white chemists fexofenadine | Trust fex | Xergic | Your pharmacy fexofenadine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alafree | Alagra | Alanil | Alerfast | Alerfex | Alfex | Axodin | Axofen | Delfex | Dinafex | Elfexo | Fastel | Fegra | Fenadin | Fenofex | Fexo | Fexocold | Fexocon | Fexodin | Fexofast | Fexofen | Fexomin | Fexona | Fexonaaf | Fexoral | Fexotab | Fexten | Fixal | Fixen | Furia | Nolargy | Odafen | Rafex | Rinofen | Ritch | Sardin | SB fexec | Telfadin | Telfast | Telfex | Vifas | X din | Xofast | Xofena</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Allegratab | Allergo Rhinathiol | Fexofenadine Sandoz | Telfast</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Telfast | Xafen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Ewofex | Telfast</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Allexofedrin | Allexofedrin pediatrico | Altiva | Cloridrato de fexofenadina | Desrinite | Fexodane | Fexolerg | Fexoliv | Fexx | Lexler | Rafex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fexo mepha allergie | Fexo pollen sandoz | Fexofenadin mepha | Fexofenadin sandoz | Fexofenadine Zentiva | Telfast | Telfastin allergo</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Rifex | Xafen | Xonadine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alexia | Allegra</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A te la | Lai duo fei | Min jie | Raltiva | Rui fei | Sai le xi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aleraliv | Alerfast | Allegra | Fentradol | Fexodina | Fexofem | Fexofenadina | Fexofenadina hcl | Fexu | Fexuped | Fexy | Garmisch fentradol | Gyets | Hismanal | Pedialab | Rinolast</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ewofex | Fexigra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fexofenaderm | Fexofenadin hexal | Fexofenadin Winthrop | Fexofenadine cipla | Telfast</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Nefoxef</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alercas | Allegra pediatrico | Fexofast | Fexofran | Ronoprin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alerfast | Alerfedine | Alexia | Allegra | Fexofen | Fexofenadina | Fexofenadina mk</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alertam | Allerfen | Allergyna | Elballerge | Fastel | Fexodine | Fexolerg | Fexon | Histafree | Histamedizen | Linofenadine | Sanzalera | Telfast</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadina cipla | Fexofenadina Tevagen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadine Bmm Pharma | Fexofenadine ratiopharm | Fexorin | Telfast</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadine Biogaran | Fexofenadine mylan | Telfast</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadine | Fexofenadine cipla | Fexofenadine Teva | Telfast | Treathay</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Allegra</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Allegix | Allerfast | Axodin | Bosnum | Fenadin | Fexet | Fexodine | Fexofenadine HCL | Fexostad | Fixdep | Telfast | Zafil</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Feksofenadinklorid cipla | Telfast</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Ewofex | Fexgen | Fexofep | Telfast</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fexomin | Fexoven | Sanolergic | Telfast | Telfast bd | Telfast hd</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fexofast | Fexofenadine | Telfast | Telfast allergy</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadine Teva | Fexofenadine trima | Telfast</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afexdine | Air | Alafex | Alecloz | Alerfex | Alernex | Alert | Alexo | Alfexo | Alifex | Allegix | Allegra | Allerfast | Allerfex | Allergix | Allergo | Allofex | Altiva | Belfexin | Cnf plus | Curifex | Delpodine | Effectin | Ethifex | Etofex | F din | Fax | Faxodas | Fegra | Fenagra | Fenixa | Fenq | Fex | Fexair | Fexeit | Fexidine | Fexigra | Fexo | Fexocet | Fexoday | Fexodin | Fexodine | Fexofast | Fexofen | Fexolife | Fexona | Fexotrol | Fexova | Fext | Fextim | Fextral | Fextro | Fexy | Finide | Finista | Fx 24 | Hhfexo | Histafree | Histagra | Histakind | Histaloc | Histeas | Histos | Klm fx | Lcfex | Nexofex | Odifex | Ofena | Ofine | Radifex | Rhinofex | Sinarest fx | Tadil | Ultigra | Verifine | Wexodine | X dine | Xaria Kidz | Zietex</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Nefoxef</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fexallegra | Fexofenadina dr reddy's | Fexofenadina MG | Fexofenadina sanofi | Fexofenadina sanofi aventis | Fixodin | Kalicet | Telfast</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Exofen | Feksine | Fexadine | Fexodex | Fexofast | Telfast</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Allegra fx | Allerbi | Fexofenadine alpha | Fexofenadine hydrochloride dk | Fexofenadine hydrochloride ffp | Fexofenadine hydrocloride bmd | Nospole rhinitis fx | Nosupol bien jyou fx | Skyblon HI</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Allegix | Allerfast | Allerfex | Allergo | Allerstat | Arest | Axodin | Bosnum | Fexet | Fexidine | Fexipas 120 | Fexo | Fexofen | Telfast | Ultigra | Xonadine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alfenadine | Allecot | Allegra | Allerdin | Alletoc | Fexigra | Fexofen | Fexomin | Fexon | Fexonadine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fexodine | Telfast</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Exofen | Fenadex | Fexofen | Telfast</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Altiva | Telfast</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Allegratab | Telfast</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Altiva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Telfast</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Afernidin | Aldifex | Allegra | Apertum OX | Biostafex | Clareve | Desrotan | Fexofenadin | Fexofenadin Landsteiner | Fexofenadina | Fexofenadina rayere | Fexoff R | Pirquet | Ranfast</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Altiva | Fexofenadin Stada | Fexofin | Fexovid | Telfast</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Allerstat | Fexet | Fexidine | Fexofenadine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Allegra Fexotabs | Fexofenadine HCL | Fexofenadine hcl amarox | Fexofenadine hcl mylan | Fexofenadine HCl Sandoz | Telfast</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Altifex | Telfast</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fexaclear | Fexofast | Hayfexo | Pharmacy health fexofenadine hayfever &amp; allergy relief | Telfast</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Allegra pediatrico | Allemax | Fenamax | Fenax | Fexaller | Fexofast | Fexofenadina | Libberafex | Xendixtal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Eofen | Fenafex | Fexet | Fexoral | Fexotab | Rhinogan | Sensitin | Telfast</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adine | Afex | Allergia | Alofex | Alrin | Altiva | Callfast | Demxet | Enadin | Faasfodine | Fanamed | Fanasel | Faxid | Faxodine | Fegix | Fenacare | Fenadex | Fendina-f | Fenix | Fenoxy | Fescot | Fexamed | Fexera | Fexet | Fexheal | Fexidine | Feximor | Fexine | Fexinol | Fexmit | Fexo | Fexofast | Fexofin | Fexokure | Fexolis | Fexolyd | Fexoprime | Fexosure | Fexsel | Fidaxo | Fifex | Fiofen | Fix it | Fixfast | Fluzip | Font | Genfix | Geridin | Hifast | Infex | Lenodine | Lixifil | Mafodin | Mb fex | Meadow | Megafast | Neofexa | Nifty | Novahist | Obfex | Odifex | Plexid | Plifast | Raltiva | Ramfex | Remast | Revofex | Saifex | Sb Din | Simfexo | Sizzle | Sneez | Softin f | Tansidin | Tefend | Telfast | Telfex | Telwin | Tilast | Vasofax | Welfast | Xadine | Xfr | Xyfex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Allegra telfast | Allertec fexo | Fexogen | Telfast | Telfexo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Allegra allergy non drowsy | Allegra hives | Allergy relief | Children's allegra allergy | Fexofenadine | Fexofenadine HCL | Mucinex allergy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fexofenadina Generis | Fexofenadina Mylan | Nalerge</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alercas | Alermid | Allegra | Allegra pediatrico | Congex | Novo alergiol | Restaler nf | Tolston nf</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Exofen | Fenadex | Fexa | Fexodine | Qfexine | Telfadin | Telfast</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Altiva | Ewofex | Telfast</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Bexist sanovel | Dinox | Fexadin | Fexo | Fexofenadine akrikhin | Telfast</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fenadex | Fexodine | Fexofin | Fexotel | Sarfex | Telfast</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Fexofenadin | Fexofenadin abacus medicine | Fexofenadin ABECE | Fexofenadin apofri | Fexofenadin Cipla | Fexofenadin Ebb | Fexofenadin orifarm | Nefoxef | Telfast</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fexofen | Telfast</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Feksofenadin Mylan | Telfast</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Ewofex | Fixit | Telfast</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Avafast | Bosnum | Fenafex | Fexofast | Medifast | Sanik | Telfast | Tofexo | Vifas</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fenadex | Telfast</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Feksine | Fexadyne | Fexofen | Mayfex | Telfast</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alledine | Fe Min | Fenadin | Fexodine | Fexofenadine | Fynadin | Jfs fct "root" | Nasaga | Naxodine | Su Min</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alexofast | Alfast | Allegra | Allergo | Altiva | Fexofen | Telfast | Tigofast</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Exofen | Fexofen | Fixdep | Xonadine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alergistin nf | Allegra | Fexofen | Norinal | Novo Alerfedine | Tolston</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alermid | Allegra | Fenax | Fexofenadina | Fexoril | Rinofen | Rinolast</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agimfast | Alerday | Allerphast | Apifexo | Fedimtast | Fefasdin | Fexodinefast | Fexophar | Gimfastnew | Hasalfast | Imexofen | Inflex | Lerphat | Loxcip | Telanhis | Telfor | Ternafast | Tinfoten | Tinifast | Tiphafast | Tocimat | Usaallerz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Afex | Fenofex | Fexaway | Fexo | Fexofenadine biotech | Telfast | Tellerge</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Allerfast | Allerstat | Fixdep | Ultigra</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Telfast</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; July 2007.</div>
</li>
<li>
<div class="reference">
                  Allegra (fexofenadine) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada; September 2006.</div>
</li>
<li>
<div class="reference">
                  Allegra Allergy 12 Hour (fexofenadine) [prescribing information]. Chatanooga, TN: Chattam; received April 2020.</div>
</li>
<li>
<div class="reference">
                  Allegra Allergy 24 Hour (fexofenadine) [prescribing information]. Chatanooga, TN: Chattam; received April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allegra.5">
<a name="Allegra.5"></a>Allegra Allergy Childrens (fexofenadine oral suspension) [prescribing information]. Chatanooga, TN: Chattam; received December 2022.</div>
</li>
<li>
<div class="reference">
                  Allegra Allergy Childrens (fexofenadine orally disintegrating tablets) [prescribing information]. Chatanooga, TN: Chattam; received February 2021.</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 94.</div>
</li>
<li>
<div class="reference">
                  Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al; American Academy of Allergy, Asthma &amp; Immunology (AAAAI); the American College of Allergy, Asthma &amp; Immunology (ACAAI); Joint Council of Allergy, Asthma &amp; Immunology. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10550755">
<a name="10550755"></a>Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. <i>J Allergy Clin Immunol</i>. 1999;104(5):1071-1078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/10550755/pubmed" id="10550755" target="_blank">10550755</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219837">
<a name="18219837"></a>Hampel FC, Kittner B, van Bavel JH. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. <i>Ann Allergy Asthma Immunol</i>. 2007;99(6):549-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/18219837/pubmed" id="18219837" target="_blank">18219837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15984599">
<a name="15984599"></a>Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. <i>Ann Allergy Asthma Immunol</i>. 2005;94(6):662-669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/15984599/pubmed" id="15984599" target="_blank">15984599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2021">
<a name="Khan.2021"></a>Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26844216">
<a name="26844216"></a>Lee XH, Ong LX, Cheong JY, et al. A stepwise approach in the management of chronic spontaneous urticaria in children. <i>Asia Pac Allergy</i>. 2016;6(1):16-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/26844216/pubmed" id="26844216" target="_blank">26844216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7712667">
<a name="7712667"></a>Lucas BD Jr, Purdy CY, Scarim SK, et al. Terfenadine pharmacokinetics in breast milk in lactating women. <i>Clin Pharmacol Ther</i>. 1995;57(4):398-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/7712667/pubmed" id="7712667" target="_blank">7712667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9506246">
<a name="9506246"></a>Markham A, Wagstaff AJ. Fexofenadine. <i>Drugs</i>. 1998;55(2):269-274; discussion 275-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/9506246/pubmed" id="9506246" target="_blank">9506246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15209959">
<a name="15209959"></a>Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies. <i>Pediatr Allergy Immunol</i>. 2004;15(3):253-260. doi:10.1111/j.1399-3038.2004.00167.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/15209959/pubmed" id="15209959" target="_blank">15209959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10831005">
<a name="10831005"></a>Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. <i>Ann Allergy Asthma Immunol</i>. 2000;84(5):517-522. doi:10.1016/S1081-1206(10)62515-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/10831005/pubmed" id="10831005" target="_blank">10831005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema.<i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pozzo-Magaña BR. Chronic urticaria in children: a review. <i>EMJ Dermatol</i>. 2017;5(1):74-82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15548781">
<a name="15548781"></a>Simons FE. Advances in H<sub>1</sub>-antihistamines. <i>N Engl J Med</i>. 2004;351(21):2203-2217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/15548781/pubmed" id="15548781" target="_blank">15548781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8977506">
<a name="8977506"></a>Simons FE, Bergman JN, Watson WT, Simons KJ. The clinical pharmacology of fexofenadine in children. <i>J Allergy Clin Immunol</i>. 1996;98(6, pt 1):1062-1064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/8977506/pubmed" id="8977506" target="_blank">8977506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28570227">
<a name="28570227"></a>Teo SL, Santosa A, Bigliardi PL. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap induced by fexofenadine. <i>J Investig Allergol Clin Immunol</i>. 2017;27(3):191-193. doi:10.18176/jiaci.0158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/28570227/pubmed" id="28570227" target="_blank">28570227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25453994">
<a name="25453994"></a>Thomson BK, Nolin TD, Velenosi TJ, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.<i> Am J Kidney Dis.</i> 2015;65(4):574-582. doi:10.1053/j.ajkd.2014.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/25453994/pubmed" id="25453994" target="_blank">25453994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12704355">
<a name="12704355"></a>Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. <i>J Allergy Clin Immunol</i>. 2003;111(4):763-769. doi:10.1067/mai.2003.1384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/12704355/pubmed" id="12704355" target="_blank">12704355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414. doi:10.1111/all.13397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexofenadine-pediatric-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13300 Version 666.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
